Anti-CYP3A5 抗体 [EPR4396] (ab108624)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR4396] to CYP3A5
- Suitable for: WB, IP, IHC-P
- Reacts with: Human
Related conjugates and formulations
製品の概要
-
製品名
Anti-CYP3A5 antibody [EPR4396]
CYP3A5 一次抗体 製品一覧 -
製品の詳細
Rabbit monoclonal [EPR4396] to CYP3A5 -
由来種
Rabbit -
アプリケーション
適用あり: WB, IP, IHC-Pmore details -
種交差性
交差種: Human -
免疫原
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
ポジティブ・コントロール
- WB: Human fetal liver and colon tissue lysates. IHC-P: Human liver and kidney tissues. IP: Human fetal liver tissue lysate.
-
特記事項
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. -
バッファー
pH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 40% Glycerol (glycerin, glycerine), 59% PBS, 0.05% BSA -
Concentration information loading...
-
精製度
Protein A purified -
ポリ/モノ
モノクローナル -
クローン名
EPR4396 -
アイソタイプ
IgG -
研究分野
関連製品
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab108624の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
WB |
1/1000. Predicted molecular weight: 57 kDa.
For unpurified use at 1/400. |
|
IP |
1/50.
For unpurified use at 1/20. |
|
IHC-P |
1/250. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
See IHC antigen retrieval protocols. For unpurified use at 1/80. |
特記事項 |
---|
WB
1/1000. Predicted molecular weight: 57 kDa. For unpurified use at 1/400. |
IP
1/50. For unpurified use at 1/20. |
IHC-P
1/250. Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol. See IHC antigen retrieval protocols. For unpurified use at 1/80. |
ターゲット情報
-
機能
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. -
配列類似性
Belongs to the cytochrome P450 family. -
細胞内局在
Endoplasmic reticulum membrane. Microsome membrane. - Information by UniProt
-
参照データベース
- Entrez Gene: 1577 Human
- Omim: 605325 Human
- SwissProt: P20815 Human
- Unigene: 695915 Human
-
別名
- Aryl hydrocarbon hydroxylase antibody
- CP35 antibody
- CP3A5_HUMAN antibody
see all
画像
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of normal human colon tissue labelling CYP3A5 with unpurified ab108624. Positive staining is shown.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
-
Anti-CYP3A5 antibody [EPR4396] (ab108624) at 1/400 dilution (unpurified) + Human fetal liver tissue lysate at 20 µg
Secondary
HRP-conjugated anti-rabbit IgG, specific to the non-reduced form of IgG at 1/1000 dilution
Predicted band size: 57 kDa
Observed band size: 52 kDa why is the actual band size different from the predicted?Blocking buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM /TBST.
-
ab108624 (unpurified) at 1/20 immunoprecipitating CYP3A5 in human fetal liver tissue lysate (Lane 1). Lane 2 - PBS. For western blotting, a HRP-conjugated anti-rabbit IgG, specific to the non-reduced form of IgG was used as the secondary antibody (1/1500).
Blocking buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM /TBST.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human liver tissue labelling CYP3A5 with unpurified ab108624 at 1/80. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. A prediluted HRP-polymer conjugated anti-rabbit IgG was used as the secondary antibody. Counterstained with Hematoxylin.
-
Anti-CYP3A5 antibody [EPR4396] (ab108624) at 1/1000 dilution (purified) + Human fetal liver tissue lysate at 20 µg
Secondary
HRP-conjugated anti-rabbit IgG, specific to the non-reduced form of IgG at 1/1000 dilution
Predicted band size: 57 kDa
Observed band size: 52 kDa why is the actual band size different from the predicted?Blocking buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM /TBST.
-
ab108624 (purified) at 1/50 immunoprecipitating CYP3A5 in human fetal liver tissue lysate (Lane 1). Lane 2 - PBS. For western blotting, a HRP-conjugated anti-rabbit IgG, specific to the non-reduced form of IgG was used as the secondary antibody (1/1500).
Blocking buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM /TBST.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of normal human kidney tissue labelling CYP3A5 with unpurified ab108624. Positive staining is shown.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
-
All lanes : Anti-CYP3A5 antibody [EPR4396] (ab108624) at 1/1000 dilution (unpurified)
Lane 1 : Human fetal liver tissue lysate
Lane 2 : Human fetal colon tissue lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 57 kDa -
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of normal human breast tissue labelling CYP3A5 with unpurified ab108624. Negative staining is shown.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human skeletal muscle tissue labelling CYP3A5 with unpurified ab108624. Negative staining is shown.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of normal human tonsil tissue labelling CYP3A5 with unpurified ab108624. Negative staining is shown.
Perform heat mediated antigen retrieval with Tris/EDTA buffer pH 9.0 before commencing with IHC staining protocol.
-
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human liver tissue labelling CYP3A5 with purified ab108624 at 1/250. Heat mediated antigen retrieval was performed using Tris/EDTA buffer pH 9. A prediluted HRP-polymer conjugated anti-rabbit IgG was used as the secondary antibody. Counterstained with Hematoxylin.
プロトコール
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (7)
ab108624 は 7 報の論文で使用されています。
- Wright WC et al. Clobetasol Propionate Is a Heme-Mediated Selective Inhibitor of Human Cytochrome P450 3A5. J Med Chem 63:1415-1433 (2020). PubMed: 31965799
- Wang L et al. miR-543 acts as a novel oncogene in oral squamous cell carcinoma by targeting CYP3A5. Oncol Rep 42:973-990 (2019). PubMed: 31322243
- Ou B et al. TLR9 rs352139 Genetic Variant Promotes Tacrolimus Elimination in Chinese Liver Transplant Patients During the Early Posttransplantation Period. Pharmacotherapy 39:67-76 (2019). PubMed: 30537010
- Zhang T et al. Association of donor small ubiquitin-like modifier 4 rs237025 genetic variant with tacrolimus elimination in the early period after liver transplantation. Liver Int 38:724-732 (2018). PubMed: 28941036
- Oladimeji PO et al. RNA interference screen identifies NAA10 as a regulator of PXR transcription. Biochem Pharmacol 160:92-109 (2018). PubMed: 30566892
- Zhang X et al. A tryptophan derivative, ITE, enhances liver cell metabolic functions in vitro. Int J Mol Med 39:101-112 (2017). PubMed: 27959388
- Fanni D et al. Immunohistochemical markers of CYP3A4 and CYP3A7: a new tool towards personalized pharmacotherapy of hepatocellular carcinoma. Eur J Histochem 60:2614 (2016). PubMed: 27349315